Physician profile

Mark L Skory

Family Medicine · Auburn, MI

NPI 1417038449

$429.72

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$17.71
Education$15.22

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $95.32 2019-2022
Lilly USA, LLC $84.42 2020-2023 Mounjaro
Janssen Pharmaceuticals, INC $60.61 2020-2022
Takeda Pharmaceuticals U.S.A., INC. $48.70 2022-2024 Gattex
Pfizer INC. $40.19 2020-2021
Kowa Pharmaceuticals America, INC. $26.69 2022
Novartis Pharmaceuticals Corporation $22.39 2021
Esperion Therapeutics, INC. $19.28 2021
Abbvie INC. $17.67 2021
Bayer Healthcare Pharmaceuticals INC. $14.45 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark L Skory

$429.72

in general payments reported 2019-2025

Years
2019-2024
Top company
Novo Nordisk INC

https://glasscript.com/doctor/517575/mark-l-skory

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.